SANOFI CONS HEALTHC IND L SANOFICONR NSEPHARMA
Company Overview
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
Why Investors Should Care
Generates a return on equity of 62.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 77.0%.
Net profit has compounded at 20.7% per year over the last five years.
Revenue has grown at a 27.0% CAGR over the past five years.
Maintains a net profit margin of 27.4%.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of ₹878.00 Cr (+22.6% YoY); net profit ₹240.10 Cr.
- Trailing 12 Months Year-on-year growth — revenue +22.6%, earnings +32.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.0%, profit CAGR 20.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.01% |
| 1 Year: | 22.59% |
Compounded Profit Growth
| 5 Years: | 20.67% |
| 1 Year: | 32.65% |
Stock Price Performance
| 1 Year: | -12.39% |
| 6 Months: | +4.93% |
| 3 Months: | -2.77% |
| 1 Month: | -2.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.75 · Neutral
P/E of 43.43 is above the sector median of 39.97 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 62.5%.
- Healthy ROCE of 77.0%.
- Excellent profit margin of 27.4%.
- Compounding revenue at 27.0% over 5 years.
- Profit CAGR of 20.7% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SANOFICONR SANOFI CONS HEALTHC IND L NSEPHARMA | 4,528.20 | 43.43 | ₹10,428.73 Cr | 1.64% | 77.02% | 62.53% | 27.01% | 20.67% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 172.60 Cr | 220.90 Cr | 233.90 Cr | 251.00 Cr | 229.20 Cr |
| Cost of Revenue | 38.80 Cr | 61.20 Cr | 61.80 Cr | 68.30 Cr | 56.20 Cr |
| Gross Profit | 133.80 Cr | 159.70 Cr | 172.10 Cr | 182.70 Cr | 173.00 Cr |
| Operating Expenses | 71.80 Cr | 92.50 Cr | 90.40 Cr | 96.30 Cr | 87.40 Cr |
| Operating Income | 62.00 Cr | 67.20 Cr | 81.70 Cr | 86.40 Cr | 85.60 Cr |
| EBITDA | 69.20 Cr | 82.40 Cr | 88.00 Cr | 94.40 Cr | 94.40 Cr |
| Interest Expense | 40.00 L | 50.00 L | 60.00 L | 50.00 L | 50.00 L |
| Pretax Income | 66.80 Cr | 78.90 Cr | 84.10 Cr | 90.50 Cr | 90.70 Cr |
| Tax Provision | 16.80 Cr | 18.20 Cr | 21.20 Cr | 24.00 Cr | 22.90 Cr |
| Net Income | 50.00 Cr | 60.70 Cr | 62.90 Cr | 66.50 Cr | 67.80 Cr |
| Diluted EPS | 21.69 | 26.36 | 27.31 | 28.87 | 29.44 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 544.30 Cr | 716.20 Cr | 878.00 Cr |
| Cost of Revenue | 194.00 Cr | 228.80 Cr | 279.80 Cr |
| Gross Profit | 350.30 Cr | 487.40 Cr | 598.20 Cr |
| Operating Expenses | 133.10 Cr | 221.20 Cr | 300.80 Cr |
| Operating Income | 217.20 Cr | 266.20 Cr | 297.40 Cr |
| EBITDA | 221.30 Cr | 255.30 Cr | 334.10 Cr |
| Interest Expense | 20.00 L | 4.00 Cr | 2.10 Cr |
| Pretax Income | 219.30 Cr | 246.80 Cr | 320.30 Cr |
| Tax Provision | 54.40 Cr | 65.80 Cr | 80.20 Cr |
| Net Income | 164.90 Cr | 181.00 Cr | 240.10 Cr |
| Diluted EPS | 71.60 | 78.59 | 104.27 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 345.40 Cr | 431.30 Cr | 547.00 Cr |
| Current Assets | 335.20 Cr | 391.70 Cr | 494.30 Cr |
| Cash & Equivalents | 1.60 Cr | 326.90 Cr | 374.80 Cr |
| Inventory | 96.60 Cr | 40.90 Cr | 61.90 Cr |
| Receivables | 31.60 Cr | 13.70 Cr | 29.60 Cr |
| Total Liabilities | 137.80 Cr | 158.30 Cr | 163.00 Cr |
| Current Liabilities | 129.90 Cr | 130.60 Cr | 128.40 Cr |
| Long Term Debt | - | - | - |
| Total Debt | 0 | 20.30 Cr | 24.80 Cr |
| Total Equity | 207.60 Cr | 273.00 Cr | 384.00 Cr |
| Shares Outstanding | 2.30 Cr | 2.30 Cr | 2.30 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -40.00 L | 439.00 Cr | 174.80 Cr |
| Investing Cash Flow | 0 | 1.90 Cr | 7.60 Cr |
| Financing Cash Flow | 2.00 Cr | -115.60 Cr | -134.50 Cr |
| Capital Expenditure | -4.00 Cr | -9.90 Cr | -7.60 Cr |
| Free Cash Flow | -4.40 Cr | 429.10 Cr | 167.20 Cr |
| Net Change in Cash | 1.60 Cr | 325.30 Cr | 47.90 Cr |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 64.4% | 68.1% | 68.1% |
| Operating Margin % | 39.9% | 37.2% | 33.9% |
| Net Margin % | 30.3% | 25.3% | 27.3% |
| ROE % | 79.4% | 66.3% | 62.5% |
| ROCE % | 100.8% | 88.5% | 71.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SANOFICONR
Is It Worth Considering Sanofi Consumer Healthcare India Limited (NSE:SANOFICONR) For Its Upcoming Dividend? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxQcjQyVngyQk82d01ILU0zR3Bad2RxQjhvRFROZWhTUkNlQ0ZNZjFNdmhMZUFpWHE4WkpYT3ZuOVZfdWY3Z05TRktoRkgxYzJmYWxkS1ZGMmtQMUY3YnBrSnV3TWpjVXdwanN6U1BuVjRvWnVsU2Y0Q0xsWWNRcFNDSzBsNTVwZVY2bjduRH…
These 4 Measures Indicate That Sanofi Consumer Healthcare India (NSE:SANOFICONR) Is Using Debt Safely - simplywall.st
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxNTEROWjExdDhxdUp2eE80WFBNTHMwOGVhSlVha1NaNDFrajM2c00xanJrUVE5czlzbU02bWdwdUUtMXFxc3c5U0tPWDhDUHlOeHNuWmlqa040XzZtUWJOVjNyZXRkOTVhVEJzWTR6ZTd3cHJEOHlRY0tRMlhqYVFBdTdobFV0ZlF6ZWJ5V2…
Sanofi Consumer Healthcare India Q4 FY25 Result: Share Price Jump 15.10%, ₹75 Dividend Declared - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTFBzV2JzN2lNWUU0ZlVnMDNvaDhzSDV0UWJCRzNNcUxmMVkzZzVsRl9DcHZqV21TdTB4TENkQWQzdEJjb3AycmdHSmV1MFVYdGRIMFNveFVCZElUTEVDZUVsc2lfNWhlbkxQLUtfVF8yUEw3bzhRc1RNSDFEdy0?oc=5" target="_blank">…
Are You Holding Sanofi Consumer Healthcare India Shares? Be Ready To Get A Huge Dividend of Rs. 75; Buy Now? - Goodreturns
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxObUkxNUt6QUk2UmVJUlFsaXYtaEFwMHN2c2ZQeWU0aUVwWnc3blV2T3c2Q0w3Mjl4MXNsNHRKdUp0QUdGX2l6aWJhQ0pJNnUtS211T3pkUFRtT0lCSHVzUnltSlhmb3NLZVdlbGNkLXJhMHFQbnFibkxkMkRaanA3YkFBbVpOQTBDUUxQLU…
Sanofi Consumer Healthcare Q2 Profit Up 21%; Stock Soars - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOREU0WDVGWGh3UzBYdV83Q3hrOUxfS090cW5rSEtsc3NFdW1STmRoaUpsWVp4YWFJZVg3S0h5XzRXVTlxWEV0UFFBb0tCaE92d3M4djd2dmZDQ2xlMlhEV0EwbUhYZ191X0NLVzRqaWhTd29MQlM0cVgzTXNKejlGeVJLYnJUREQwQUJETU…
Sanofi Consumer Healthcare India Ltd. Share Price Live Today - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPU0tsMV9hYjdHRlR3MHBKWnhMM2FHeF9OLVowY2l1cFJTempPdVNYU3NuNnFqdS1hNFhjc25wY3JGeDJZOElDODZEaTFZVUhQNm5Kd2ZWekdwQUhGNjgtT0I1Qkk3V0UwNlFUeE9ZUDB5c24wNC1pbDJvUEtXMlp4a3ZqQ1h1MGUtLW9hNm…
SANOFICONR — Frequently Asked Questions
What is the current share price of SANOFI CONS HEALTHC IND L (SANOFICONR)?
As of 2026-07-15 09:52 IST, SANOFI CONS HEALTHC IND L (SANOFICONR) trades at ₹4,528.20 on NSE. Its 52-week range is ₹3,938.88 to ₹5,285.17.
What is the market capitalisation of SANOFICONR?
SANOFI CONS HEALTHC IND L (SANOFICONR) has a market capitalisation of ₹10,428.73 Cr on NSE.
What is the P/E ratio of SANOFICONR?
SANOFICONR trades at a trailing price-to-earnings (P/E) ratio of 43.43. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 27.52.
Does SANOFICONR pay a dividend?
SANOFI CONS HEALTHC IND L (SANOFICONR) currently offers a dividend yield of 1.64%.
What is the return on equity (ROE) of SANOFICONR?
SANOFICONR has a return on equity (ROE) of 62.53%. Its return on capital employed (ROCE) is 77.02%.
Is SANOFICONR a good stock to buy?
This page provides a data-driven analysis of SANOFI CONS HEALTHC IND L (SANOFICONR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.